Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2019
At a glance
- Drugs Donanemab (Primary) ; LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms TRAILBLAZER-ALZ
- Sponsors Eli Lilly
- 18 Oct 2018 Planned number of patients changed from 375 to 266.
- 14 Aug 2018 Planned End Date changed from 23 Dec 2020 to 16 Sep 2021.
- 14 Aug 2018 Planned primary completion date changed from 4 Mar 2020 to 15 Oct 2020.